Description
A PPARγ agonist (EC50 = 8.83 nM in a transactivation assay); selective for PPARγ over PPARα, PPARβ/δ, and RXRα at 10 µM; decreases serum levels of glucose, triglycerides, non-esterified fatty acids, and insulin and increases hepatic palmitate oxidation in an ob/ob mouse model of type 2 diabetes at 30 mg/kg per day; decreases plasma levels of triglycerides and total and non-HDL cholesterol and the surface area of atherosclerotic lesions in the aortic sinus in an E2-KI transgenic mouse model of dyslipidemia and atherosclerosis fed a Western diet at 30 mg/kg